Clinical Trial

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

Name: The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT — clinical trial record (NCT07126782)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.

Trial Details

NCT Number	NCT07126782
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	AML (Acute Myelogenous Leukemia), AML
Enrollment	10 participants
Start Date	2025-07-20
Primary Completion	2027-12-20 (estimated)
Study Completion	2028-07-20 (estimated)
Updated on ClinicalTrials.gov	2025-08-17